2 results match your criteria: "Affiliated Taizhou Hospital of Wenzhou Medical University Taizhou 317000[Affiliation]"
Phase I study of icotinib, an EGFR tyrosine kinase inhibitor combined with IMRT in nasopharyngeal carcinoma.
Int J Clin Exp Med
December 2015
Department of Radiation Oncology, Affiliated Taizhou Hospital of Wenzhou Medical University Taizhou 317000, China ; Laboratory of Cellular and Molecular Radiation Oncology, Affiliated Taizhou Hospital of Wenzhou Medical University Taizhou 317000, China.
Background: Epidermal growth factor receptor (EGFR) is a new target for nasopharyngeal carcinoma (NPC) therapy. This prospective phase I study sought to determine the safety and recommended phase II dose of icotinib, a novel highly selective oral EGFR tyrosine kinase inhibitor, in combination with intensity-modulated radiotherapy (IMRT) in patients with NPC.
Methods: Eligible patients with NPC received escalating doses of icotinib during IMRT.
Prognostic correlation between MTA2 expression level and colorectal cancer.
Int J Clin Exp Pathol
May 2016
Department of Radiotherapy and Oncology, The Second Affiliated Hospital of Soochow University Suzhou 215004, China.
Objectives: Association of MTA2 expression with presence, development, metastasis and prognosis of colorectal cancer (CRC) was investigated.
Methods: 90 CRC-related cases with follow-up information were made into tissue microarrays according to the paired principle of cancer tissues and the adjacent tissues. Subsequently, the expression of MAT2 was detected with immunohistochemical analysis and SPSS software was finally utilized to analyze the relationships between experimental data and clinical indicatives.